Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Net Margin
Jamjoom Pharmaceuticals Factory Company SJSC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SA |
J
|
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
|
10.9B SAR |
30%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
776.5B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.9B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.5B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.4B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
170.3B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.5B USD |
13%
|
Jamjoom Pharmaceuticals Factory Company SJSC
Glance View
Jamjoom Pharmaceuticals Factory Company SJSC, nestled in the heart of Saudi Arabia, has emerged as a formidable player in the Middle East's pharmaceutical landscape. Founded in 1994, the company was borne out of a vision to cater to the growing healthcare demands of the region, leveraging both high-tech manufacturing and rigorous scientific research. Initially focused on generic medications, Jamjoom Pharmaceuticals has since expanded its portfolio to include a diverse range of products from ophthalmology to dermatology. With a state-of-the-art manufacturing facility in Jeddah, it integrates advanced technologies into its processes, ensuring that its products meet global quality standards. The company's adherence to Good Manufacturing Practices (GMP) and its drive to innovate are reflected in its collaborations with international partners for research and development, exemplifying its commitment to producing affordable, high-quality medications. At the core of Jamjoom Pharmaceuticals' business model is a robust distribution network that spans across the Middle East and North Africa (MENA) region, facilitating seamless supply chain operations. Revenue is generated primarily through the sale of its diversified product line, which includes prescription medications, over-the-counter solutions, and specialized healthcare products. The company leverages relationships with hospitals, healthcare providers, and retail pharmacies to enhance its market penetration. Its strategic focus on emerging therapeutic areas and persistent efforts to expand its international presence are paying dividends as it grows its footprint beyond the MENA region. By consistently reinvesting in research and development, Jamjoom Pharmaceuticals keeps its pipeline replenished with innovations that not only promise to enhance patient outcomes but also ensure sustainable profitability in a competitive pharmaceutical market.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Jamjoom Pharmaceuticals Factory Company SJSC's most recent financial statements, the company has Net Margin of 29.5%.
You don't have any saved screeners yet